In plain terms: Fenugreek (Trigonella foenum-graecum) has some human trial evidence supporting it, but the evidence is not yet strong enough for EBL to call it established. It is worth knowing about and worth discussing with your clinician.
Fenugreek (Trigonella foenum-graecum)
The evidence as the record states it
Kim et al. (Int J Mol Sci, 2023; PMID 37762302): meta-analysis of 10 randomized trials, 706 participants with type 2 diabetes or prediabetes; fenugreek lowered fasting glucose, 2-hour glucose and HbA1c, with no change in HOMA-IR. Fakhr et al. (Pharmacol Res, 2023; PMID 36470549): meta-analysis of 29 randomized trials; fasting plasma glucose 16.75 mg/dL lower. Neelakantan et al. (Nutr J, 2014; PMID 24438170): 10 trials; fasting glucose 0.96 mmol/L and HbA1c 0.85 percent lower, with the effect confined to medium or high doses in people with diabetes and most trials of low methodological quality. Shabil et al. (Medicina (Kaunas), 2023; PMID 36837450): 14 trials, 894 participants; HbA1c 0.88 lower, while fasting glucose (P = 0.76) and after-meal glucose (P = 0.72) did not change. Grade B: replicated across independent pooled analyses on glycemic surrogates, with one pooled analysis null on fasting glucose and trial quality mostly low.
Why Grade B and not Grade A
Grade B reflects moderate human evidence -- typically a single strong trial, multiple smaller trials, or surrogate endpoint data without hard clinical outcome replication. To reach Grade A, Fenugreek (Trigonella foenum-graecum) would require at least one additional independent randomized trial demonstrating a hard clinical endpoint or objectively measured functional outcome in a comparable population.
What would move this grade
An independent randomized trial demonstrating a hard clinical endpoint -- mortality, major adverse event, or objectively confirmed functional improvement -- in an adequately powered sample, with results independently replicated, would support Grade A.
How this was studied
Form: Fenugreek seed or seed powder, against a control intervention (Neelakantan 2014 meta-analysis, PMID 24438170); preparations were not standardized across trials (Neelakantan 2014, PMID 24438170). · Dose: Medium or high seed doses in the trials where fasting and 2-hour glucose fell; the exact gram amounts are not stated in the cited abstracts (Neelakantan 2014, PMID 24438170). · Population: Adults with type 2 diabetes or prediabetes: 10 randomized trials, 706 participants (Kim 2023, PMID 37762302); 29 randomized trials across metabolic syndrome components (Fakhr 2023, PMID 36470549); 14 trials, 894 participants (Shabil 2023, PMID 36837450). · Duration: At least 1 week by the inclusion rule of one pooled analysis; trial lengths are not otherwise stated in the cited abstracts (Neelakantan 2014, PMID 24438170).